Addex ADX10061 Receives £1.2 million Funding for Manufacture and Investigator Led Clinical Studies as part of the Tools for Human Drug and Brain Research (THuNDR2) Initiative from the Wellcome Trust
September 20, 2018 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, 20 September 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that it has joined the...
Addex’s Selective mGlu2 PAM ADX71149 Shows Promise in Treating Severe Panic Disorders and PTSD
September 04, 2018 01:00 ET
|
Addex Therapeutics
Preclinical and Adhoc Clinical Data Published in Molecular Psychiatry Geneva, Switzerland, 4 September 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric...
Van Leeuwenhoeck Issues Equity Research Note Highlighting Addex Investment Opportunity
July 12, 2018 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, 12 July 2018 – Addex Therapeutics (SIX: ADXN) announced today that the independent life science research company Van Leeuwenhoeck has issued an equity research note...
Addex Shareholders Approve All Resolutions at Annual General Meeting
June 21, 2018 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 21 June 2018 -...
Addex Reports 2017 Full Year Results and Provides Corporate Update
April 30, 2018 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Robust cash position of CHF45 million...
Addex Sucessfully Raises CHF40 million in Capital Increase
March 29, 2018 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 29 March 2018 -...
Swiss Takeover Board Validates New Article 39 (Opting-Out Provision) of Addex Articles of Association
March 20, 2018 13:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Preliminary note: this Press Release...
Addex Shareholders Approved all Board Proposals at Extraordinary General Meeting
March 19, 2018 02:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 19 March 2018 -...
Addex Secures Investor Commitment for CHF40 million Capital Increase Following Successful Completion of Book Building Process
March 05, 2018 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 5 March 2018 -...
Addex Publishes Extraordinary General Meeting Invitation
February 23, 2018 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 23 February 2018...